Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2016

View Archived Issues

AS03-adjuvanted GlaxoSmithKline H7N9 pandemic influenza vaccine induces robust antibody responses

REDUCE-IT study of Amarin's Vascepa to continue as planned

Medicines for Malaria Venture initiates first-in-human trial of P-218

Circle Pharma and Pfizer enter agreement to build screening library of macrocyclic peptides

Bioblast Pharma reports results from extension study of trehalose in OPMD

Voyager Therapeutics enters collaboration to advance VY-HTT01 program

Semma Therapeutics receives grant for personalized cell therapy for diabetes

Phase II study of Flex Pharma's FLX-787 in ALS begins

FDA awards fast track designation to Aptinyx's NYX-2925

Ligand Pharmaceuticals initiates phase II study of LGD-6972

AmpliPhi Biosciences's AB-SA01 well tolerated in phase I study

Oxford Gene Technology launches new FISH probes for lung cancers

MMRF and Memorial Sloan Kettering collaborate on minimal residue disease trial

ANA positivity combined with anti-DFS70 negativity may be associated with CTD in NSIP patients

Dual GLP-1R/glucagon receptor agonist MOD-6031 enters phase I development for obesity

Morphotek and Fox Chase Cancer Center enter research agreement

European Commission approves Cabometyx for advanced renal cell carcinoma

CDRD launches new company developing novel rapid sepsis diagnostic

Cellectar Biosciences' CLR-131 to be evaluated in head and neck cancers

BioChaperone Combo reduces postprandial glucose and hyperglycemia risk in type 1 diabetes

MicroRNA 132 can be targeted to improve pressure-induced heart failure

Nanobiotix files for approval of NBTXR-3 in Europe

Hexanal shows potential as an inflammation biomarker

Bayer's emodepside granted U.S. orphan status for onchocerciasis

5-HETE and 5-oxoETE show potential for OSA screening

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...